Global
Product Overview
CSL Behring develops, manufactures and markets protein based therapies, including:
Bleeding Disorders Therapies
Fluid Replacement Therapies
Hereditary Angioedema (HAE) Therapies
Immunoglobulin Therapies
Pulmonary Therapies
Wound Healing Therapies
Global Product Portfolio
Features
Policy Impact-Europe Winter 2013
null
Synergy Exists Amongst Public Policies in Europe and US
Personal Stories
Personal Stories
Retired Teacher and Coach Cycles for Alpha-1 Awareness
Policy Impact-US Winter 2013
Personal Stories
Public Policy Issues in US that Impact Access to Care
Corporate Responsibility Report
Corporate Responsibility Report
CSL sustains the community as well as the business
News
30-Apr-2013
Kcentra™ Approved by FDA for Urgent Warfarin Reversal
16-Apr-2013
Berinert® Wins EMA Approval for Short-Term Prophy Label
04-Apr-2013
Privigen® Gains Approval for CIDP in Europe
03-Apr-2013
CSL Behring Continues to Donate Factor Product to WFH GAP Program
28-Feb-2013
FDA Approves Expanded Indication for Corifact®
View all news